APO Research
Talk to an analyst

APO RESEARCH · REPORT

In-Vitro Cancer Diagnostics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global In-Vitro Cancer Diagnostics Market Outlook and Growth Opportunities 2026

19 December 2025194 pages

Choose your research edition.

Industry ResearchIn-Vitro Cancer Diagnostics Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal In-Vitro Cancer Diagnostics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal In-Vitro Cancer Diagnostics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal In-Vitro Cancer Diagnostics Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal In-Vitro Cancer Diagnostics Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global In-Vitro Cancer Diagnostics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for In-Vitro Cancer Diagnostics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for In-Vitro Cancer Diagnostics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for In-Vitro Cancer Diagnostics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the In-Vitro Cancer Diagnostics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the In-Vitro Cancer Diagnostics market include Abbott Laboratories, Beckman Coulter, Epigenomics AG, MDx Health Quest Diagnostics, Randox Laboratories, R-Biopharm AG, Signature Diagnostics, Amoy Diagnostics Co.,Ltd. and Daan Gene, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global In-Vitro Cancer Diagnostics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of In-Vitro Cancer Diagnostics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents In-Vitro Cancer Diagnostics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global In-Vitro Cancer Diagnostics market.

In-Vitro Cancer Diagnostics Segment by Company

Abbott Laboratories

Beckman Coulter

Epigenomics AG

MDx Health Quest Diagnostics

Randox Laboratories

R-Biopharm AG

Signature Diagnostics

Amoy Diagnostics Co.,Ltd.

Daan Gene

Fosun Pharma

Novogene

Burning Rock

Geneseeq

Siemens Healthcare

In-Vitro Cancer Diagnostics Segment by Type

Instruments

Reagents and Kits

In-Vitro Cancer Diagnostics Segment by Application

Laboratories

Hospitals

Others

In-Vitro Cancer Diagnostics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global In-Vitro Cancer Diagnostics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the In-Vitro Cancer Diagnostics key companies, revenue, market share, and recent developments.

3. To split the In-Vitro Cancer Diagnostics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions In-Vitro Cancer Diagnostics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify In-Vitro Cancer Diagnostics significant trends, drivers, influence factors in global and regions.

6. To analyze In-Vitro Cancer Diagnostics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global In-Vitro Cancer Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of In-Vitro Cancer Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of In-Vitro Cancer Diagnostics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global In-Vitro Cancer Diagnostics industry.

Chapter 3: Detailed analysis of In-Vitro Cancer Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of In-Vitro Cancer Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of In-Vitro Cancer Diagnostics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. In-Vitro Cancer Diagnostics Industry Trends Table 2. In-Vitro Cancer Diagnostics Industry Drivers Table 3. In-Vitro Cancer Diagnostics Industry Opportunities and Challenges Table 4. In-Vitro Cancer Diagnostics Industry Restraints Table 5. Global In-Vitro Cancer Diagnostics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global In-Vitro Cancer Diagnostics Revenue Share by Company (2021-2026) Table 7. Global In-Vitro Cancer Diagnostics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global In-Vitro Cancer Diagnostics Key Company Manufacturing Base & Headquarters Table 9. Global In-Vitro Cancer Diagnostics Company, Product Type & Application Table 10. Global In-Vitro Cancer Diagnostics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global In-Vitro Cancer Diagnostics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Instruments Table 15. Significant Companies of Reagents and Kits Table 16. Global In-Vitro Cancer Diagnostics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global In-Vitro Cancer Diagnostics Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global In-Vitro Cancer Diagnostics Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global In-Vitro Cancer Diagnostics Sales Value Share by Type (2021-2026) Table 20. Global In-Vitro Cancer Diagnostics Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Laboratories Table 22. Significant Companies of Hospitals Table 23. Significant Companies of Others Table 24. Global In-Vitro Cancer Diagnostics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global In-Vitro Cancer Diagnostics Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global In-Vitro Cancer Diagnostics Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global In-Vitro Cancer Diagnostics Sales Value Share by Application (2021-2026) Table 28. Global In-Vitro Cancer Diagnostics Sales Value Share by Application (2027-2032) Table 29. Global In-Vitro Cancer Diagnostics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global In-Vitro Cancer Diagnostics Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global In-Vitro Cancer Diagnostics Sales Value Share by Region (2021-2026) Table 32. Global In-Vitro Cancer Diagnostics Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global In-Vitro Cancer Diagnostics Sales Value Share by Region (2027-2032) Table 34. Global In-Vitro Cancer Diagnostics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global In-Vitro Cancer Diagnostics Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global In-Vitro Cancer Diagnostics Sales Value Market Share by Country (2021-2026) Table 37. Global In-Vitro Cancer Diagnostics Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global In-Vitro Cancer Diagnostics Sales Value Market Share by Country (2027-2032) Table 39. Abbott Laboratories Company Information Table 40. Abbott Laboratories Business Overview Table 41. Abbott Laboratories In-Vitro Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Abbott Laboratories In-Vitro Cancer Diagnostics Product Portfolio Table 43. Abbott Laboratories Recent Development Table 44. Beckman Coulter Company Information Table 45. Beckman Coulter Business Overview Table 46. Beckman Coulter In-Vitro Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Beckman Coulter In-Vitro Cancer Diagnostics Product Portfolio Table 48. Beckman Coulter Recent Development Table 49. Epigenomics AG Company Information Table 50. Epigenomics AG Business Overview Table 51. Epigenomics AG In-Vitro Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Epigenomics AG In-Vitro Cancer Diagnostics Product Portfolio Table 53. Epigenomics AG Recent Development Table 54. MDx Health Quest Diagnostics Company Information Table 55. MDx Health Quest Diagnostics Business Overview Table 56. MDx Health Quest Diagnostics In-Vitro Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. MDx Health Quest Diagnostics In-Vitro Cancer Diagnostics Product Portfolio Table 58. MDx Health Quest Diagnostics Recent Development Table 59. Randox Laboratories Company Information Table 60. Randox Laboratories Business Overview Table 61. Randox Laboratories In-Vitro Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Randox Laboratories In-Vitro Cancer Diagnostics Product Portfolio Table 63. Randox Laboratories Recent Development Table 64. R-Biopharm AG Company Information Table 65. R-Biopharm AG Business Overview Table 66. R-Biopharm AG In-Vitro Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. R-Biopharm AG In-Vitro Cancer Diagnostics Product Portfolio Table 68. R-Biopharm AG Recent Development Table 69. Signature Diagnostics Company Information Table 70. Signature Diagnostics Business Overview Table 71. Signature Diagnostics In-Vitro Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Signature Diagnostics In-Vitro Cancer Diagnostics Product Portfolio Table 73. Signature Diagnostics Recent Development Table 74. Amoy Diagnostics Co.,Ltd. Company Information Table 75. Amoy Diagnostics Co.,Ltd. Business Overview Table 76. Amoy Diagnostics Co.,Ltd. In-Vitro Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Amoy Diagnostics Co.,Ltd. In-Vitro Cancer Diagnostics Product Portfolio Table 78. Amoy Diagnostics Co.,Ltd. Recent Development Table 79. Daan Gene Company Information Table 80. Daan Gene Business Overview Table 81. Daan Gene In-Vitro Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Daan Gene In-Vitro Cancer Diagnostics Product Portfolio Table 83. Daan Gene Recent Development Table 84. Fosun Pharma Company Information Table 85. Fosun Pharma Business Overview Table 86. Fosun Pharma In-Vitro Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Fosun Pharma In-Vitro Cancer Diagnostics Product Portfolio Table 88. Fosun Pharma Recent Development Table 89. Novogene Company Information Table 90. Novogene Business Overview Table 91. Novogene In-Vitro Cancer Diagnostics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Novogene In-Vitro Cancer Diagnostics Product Portfolio Table 93. Novogene Recent Development Table 94. Burning Rock Company Information Table 95. Burning Rock Business Overview Table 96. Burning Rock In-Vitro Cancer Diagnostics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Burning Rock In-Vitro Cancer Diagnostics Product Portfolio Table 98. Burning Rock Recent Development Table 99. Geneseeq Company Information Table 100. Geneseeq Business Overview Table 101. Geneseeq In-Vitro Cancer Diagnostics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Geneseeq In-Vitro Cancer Diagnostics Product Portfolio Table 103. Geneseeq Recent Development Table 104. Siemens Healthcare Company Information Table 105. Siemens Healthcare Business Overview Table 106. Siemens Healthcare In-Vitro Cancer Diagnostics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Siemens Healthcare In-Vitro Cancer Diagnostics Product Portfolio Table 108. Siemens Healthcare Recent Development Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. In-Vitro Cancer Diagnostics Product Image Figure 2. Global In-Vitro Cancer Diagnostics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global In-Vitro Cancer Diagnostics Market Size (2021-2032) & (US$ Million) Figure 4. Global In-Vitro Cancer Diagnostics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Instruments Image Figure 8. Reagents and Kits Image Figure 9. Global In-Vitro Cancer Diagnostics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global In-Vitro Cancer Diagnostics Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global In-Vitro Cancer Diagnostics Sales Value Share by Type (2021-2032) Figure 12. Laboratories Image Figure 13. Hospitals Image Figure 14. Others Image Figure 15. Global In-Vitro Cancer Diagnostics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global In-Vitro Cancer Diagnostics Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global In-Vitro Cancer Diagnostics Sales Value Share by Application (2021-2032) Figure 18. Global In-Vitro Cancer Diagnostics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global In-Vitro Cancer Diagnostics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America In-Vitro Cancer Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 21. North America In-Vitro Cancer Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe In-Vitro Cancer Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 23. Europe In-Vitro Cancer Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific In-Vitro Cancer Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific In-Vitro Cancer Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America In-Vitro Cancer Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 27. South America In-Vitro Cancer Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa In-Vitro Cancer Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa In-Vitro Cancer Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Instruments
  • Reagents and Kits
Applications
  • Laboratories
  • Hospitals
  • Others
Companies covered
  • Abbott Laboratories
  • Beckman Coulter
  • Epigenomics AG
  • MDx Health Quest Diagnostics
  • Randox Laboratories
  • R-Biopharm AG
  • Signature Diagnostics
  • Amoy Diagnostics Co.,Ltd.
  • Daan Gene
  • Fosun Pharma
  • Novogene
  • Burning Rock
  • Geneseeq
  • Siemens Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global In-Vitro Cancer Diagnostics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global In-Vitro Cancer Diagnostics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 In-Vitro Cancer Diagnostics Market Dynamics
  1. 2.1 In-Vitro Cancer Diagnostics Industry Trends
  2. 2.2 In-Vitro Cancer Diagnostics Industry Drivers
  3. 2.3 In-Vitro Cancer Diagnostics Industry Opportunities and Challenges
  4. 2.4 In-Vitro Cancer Diagnostics Industry Restraints
3 In-Vitro Cancer Diagnostics Market by Company
  1. 3.1 Global In-Vitro Cancer Diagnostics Company Revenue Ranking in 2025
  2. 3.2 Global In-Vitro Cancer Diagnostics Revenue by Company (2021-2026)
  3. 3.3 Global In-Vitro Cancer Diagnostics Company Ranking (2024-2026)
  4. 3.4 Global In-Vitro Cancer Diagnostics Company Manufacturing Base and Headquarters
  5. 3.5 Global In-Vitro Cancer Diagnostics Company Product Type and Application
  6. 3.6 Global In-Vitro Cancer Diagnostics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global In-Vitro Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 In-Vitro Cancer Diagnostics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 In-Vitro Cancer Diagnostics Market by Type
  1. 4.1 In-Vitro Cancer Diagnostics Type Introduction
  2. 4.1.1 Instruments
  3. 4.1.2 Reagents and Kits
  4. 4.2 Global In-Vitro Cancer Diagnostics Sales Value by Type
  5. 4.2.1 Global In-Vitro Cancer Diagnostics Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global In-Vitro Cancer Diagnostics Sales Value by Type (2021-2032)
  7. 4.2.3 Global In-Vitro Cancer Diagnostics Sales Value Share by Type (2021-2032)
5 In-Vitro Cancer Diagnostics Market by Application
  1. 5.1 In-Vitro Cancer Diagnostics Application Introduction
  2. 5.1.1 Laboratories
  3. 5.1.2 Hospitals
  4. 5.1.3 Others
  5. 5.2 Global In-Vitro Cancer Diagnostics Sales Value by Application
  6. 5.2.1 Global In-Vitro Cancer Diagnostics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global In-Vitro Cancer Diagnostics Sales Value by Application (2021-2032)
  8. 5.2.3 Global In-Vitro Cancer Diagnostics Sales Value Share by Application (2021-2032)
6 In-Vitro Cancer Diagnostics Regional Value Analysis
  1. 6.1 Global In-Vitro Cancer Diagnostics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global In-Vitro Cancer Diagnostics Sales Value by Region (2021-2032)
  3. 6.2.1 Global In-Vitro Cancer Diagnostics Sales Value by Region: 2021-2026
  4. 6.2.2 Global In-Vitro Cancer Diagnostics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America In-Vitro Cancer Diagnostics Sales Value (2021-2032)
  7. 6.3.2 North America In-Vitro Cancer Diagnostics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe In-Vitro Cancer Diagnostics Sales Value (2021-2032)
  10. 6.4.2 Europe In-Vitro Cancer Diagnostics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific In-Vitro Cancer Diagnostics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific In-Vitro Cancer Diagnostics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America In-Vitro Cancer Diagnostics Sales Value (2021-2032)
  16. 6.6.2 South America In-Vitro Cancer Diagnostics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa In-Vitro Cancer Diagnostics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa In-Vitro Cancer Diagnostics Sales Value Share by Country, 2025 VS 2032
7 In-Vitro Cancer Diagnostics Country-level Value Analysis
  1. 7.1 Global In-Vitro Cancer Diagnostics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global In-Vitro Cancer Diagnostics Sales Value by Country (2021-2032)
  3. 7.2.1 Global In-Vitro Cancer Diagnostics Sales Value by Country (2021-2026)
  4. 7.2.2 Global In-Vitro Cancer Diagnostics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt In-Vitro Cancer Diagnostics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt In-Vitro Cancer Diagnostics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt In-Vitro Cancer Diagnostics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott Laboratories
  2. 8.1.1 Abbott Laboratories Company Information
  3. 8.1.2 Abbott Laboratories Business Overview
  4. 8.1.3 Abbott Laboratories In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Laboratories In-Vitro Cancer Diagnostics Product Portfolio
  6. 8.1.5 Abbott Laboratories Recent Developments
  7. 8.2 Beckman Coulter
  8. 8.2.1 Beckman Coulter Company Information
  9. 8.2.2 Beckman Coulter Business Overview
  10. 8.2.3 Beckman Coulter In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Beckman Coulter In-Vitro Cancer Diagnostics Product Portfolio
  12. 8.2.5 Beckman Coulter Recent Developments
  13. 8.3 Epigenomics AG
  14. 8.3.1 Epigenomics AG Company Information
  15. 8.3.2 Epigenomics AG Business Overview
  16. 8.3.3 Epigenomics AG In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Epigenomics AG In-Vitro Cancer Diagnostics Product Portfolio
  18. 8.3.5 Epigenomics AG Recent Developments
  19. 8.4 MDx Health Quest Diagnostics
  20. 8.4.1 MDx Health Quest Diagnostics Company Information
  21. 8.4.2 MDx Health Quest Diagnostics Business Overview
  22. 8.4.3 MDx Health Quest Diagnostics In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 MDx Health Quest Diagnostics In-Vitro Cancer Diagnostics Product Portfolio
  24. 8.4.5 MDx Health Quest Diagnostics Recent Developments
  25. 8.5 Randox Laboratories
  26. 8.5.1 Randox Laboratories Company Information
  27. 8.5.2 Randox Laboratories Business Overview
  28. 8.5.3 Randox Laboratories In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Randox Laboratories In-Vitro Cancer Diagnostics Product Portfolio
  30. 8.5.5 Randox Laboratories Recent Developments
  31. 8.6 R-Biopharm AG
  32. 8.6.1 R-Biopharm AG Company Information
  33. 8.6.2 R-Biopharm AG Business Overview
  34. 8.6.3 R-Biopharm AG In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 R-Biopharm AG In-Vitro Cancer Diagnostics Product Portfolio
  36. 8.6.5 R-Biopharm AG Recent Developments
  37. 8.7 Signature Diagnostics
  38. 8.7.1 Signature Diagnostics Company Information
  39. 8.7.2 Signature Diagnostics Business Overview
  40. 8.7.3 Signature Diagnostics In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Signature Diagnostics In-Vitro Cancer Diagnostics Product Portfolio
  42. 8.7.5 Signature Diagnostics Recent Developments
  43. 8.8 Amoy Diagnostics Co.,Ltd.
  44. 8.8.1 Amoy Diagnostics Co.,Ltd. Company Information
  45. 8.8.2 Amoy Diagnostics Co.,Ltd. Business Overview
  46. 8.8.3 Amoy Diagnostics Co.,Ltd. In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Amoy Diagnostics Co.,Ltd. In-Vitro Cancer Diagnostics Product Portfolio
  48. 8.8.5 Amoy Diagnostics Co.,Ltd. Recent Developments
  49. 8.9 Daan Gene
  50. 8.9.1 Daan Gene Company Information
  51. 8.9.2 Daan Gene Business Overview
  52. 8.9.3 Daan Gene In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Daan Gene In-Vitro Cancer Diagnostics Product Portfolio
  54. 8.9.5 Daan Gene Recent Developments
  55. 8.10 Fosun Pharma
  56. 8.10.1 Fosun Pharma Company Information
  57. 8.10.2 Fosun Pharma Business Overview
  58. 8.10.3 Fosun Pharma In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Fosun Pharma In-Vitro Cancer Diagnostics Product Portfolio
  60. 8.10.5 Fosun Pharma Recent Developments
  61. 8.11 Novogene
  62. 8.11.1 Novogene Company Information
  63. 8.11.2 Novogene Business Overview
  64. 8.11.3 Novogene In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novogene In-Vitro Cancer Diagnostics Product Portfolio
  66. 8.11.5 Novogene Recent Developments
  67. 8.12 Burning Rock
  68. 8.12.1 Burning Rock Company Information
  69. 8.12.2 Burning Rock Business Overview
  70. 8.12.3 Burning Rock In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Burning Rock In-Vitro Cancer Diagnostics Product Portfolio
  72. 8.12.5 Burning Rock Recent Developments
  73. 8.13 Geneseeq
  74. 8.13.1 Geneseeq Company Information
  75. 8.13.2 Geneseeq Business Overview
  76. 8.13.3 Geneseeq In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Geneseeq In-Vitro Cancer Diagnostics Product Portfolio
  78. 8.13.5 Geneseeq Recent Developments
  79. 8.14 Siemens Healthcare
  80. 8.14.1 Siemens Healthcare Company Information
  81. 8.14.2 Siemens Healthcare Business Overview
  82. 8.14.3 Siemens Healthcare In-Vitro Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Siemens Healthcare In-Vitro Cancer Diagnostics Product Portfolio
  84. 8.14.5 Siemens Healthcare Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst